Du är här


Swedish Orphan Biovitrum AB (publ): Invitation - Presentation of Sobi's first quarter results 2014

On 8 May Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for
the first quarter 2014.

Financial analysts and media are invited to participate in a telephone
conference, which will include a presentation of the results, at 14:00 CET.
The event will be hosted by Sobi's CEO and President, Geoffrey McDonough. The
presentation will be held in English.

The presentation can be followed live, or afterwards onwww.sobi.com. Slides
used in the presentation will be made available on our website prior to the
telephone conference.

To participate in the telephone conference, please call:
SE: +46 851999365
UK: +44 2076602078
US: +18552692606



About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of
specialty and rare disease products for partner companies. Sobi is a pioneer
in biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
(€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available atwww.sobi.com.

|For more information please contact |
|Media relations Investor relations |
|Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
|T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
|oskar.bosson@sobi.com jorgen.winroth@sobi.com |
Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.